Class Action Lawsuit Filed Against ARS Pharmaceuticals Over Insurance Coverage for Neffy
A class action lawsuit has been filed against ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) by Pomerantz LLP over alleged securities fraud and other unlawful business practices involving the company's epinephrine nasal spray product neffy. The firm is urging investors who purchased or acquired shares during a specified period to contact them for potential inclusion in the lawsuit. The action follows ARS’s announcement on June 24, 2026, that it did not secure expanded insurance coverage for neffy through CVS Caremark by its July 1 deadline. This failure left the company without broader coverage during critical allergy seasons and led to a sharp drop in stock price—falling $2.52 per share (or 23.91%) on June 25, 2026. Pomerantz LLP is one of the leading firms specializing in securities litigation and has secured significant damages for class members over decades.
Tickers: $SPRY